Interpace Biosciences, Inc. (OTCMKTS:IDXG) Short Interest Update

Interpace Biosciences, Inc. (OTCMKTS:IDXG) saw a large drop in short interest in May. As of May 29th, there was short interest totaling 10 shares, a drop of 98.8% from the May 14th total of 806 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 17,136 shares, the short-interest ratio is currently 0.0 days.

Interpace Biosciences Stock Performance

IDXG stock traded up $0.06 during trading on Tuesday, reaching $1.74. The company had a trading volume of 6,642 shares, compared to its average volume of 6,259. The firm has a 50-day simple moving average of $1.92 and a 200-day simple moving average of $1.62. The company has a market cap of $7.71 million, a price-to-earnings ratio of -34.80 and a beta of 0.59. Interpace Biosciences has a twelve month low of $0.70 and a twelve month high of $2.40.

Interpace Biosciences (OTCMKTS:IDXG) last posted its quarterly earnings results on Tuesday, May 12th. The business services provider reported $0.03 earnings per share (EPS) for the quarter. Interpace Biosciences had a net margin of 65.25% and a return on equity of 219.07%. The company had revenue of $9.03 million during the quarter.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.